Status:
COMPLETED
An Assessment of Milk Thistle Pharmacokinetics and Drug Interactions
Lead Sponsor:
Medical University of South Carolina
Collaborating Sponsors:
National Center for Complementary and Integrative Health (NCCIH)
Office of Dietary Supplements (ODS)
Conditions:
Healthy
Eligibility:
All Genders
18-45 years
Brief Summary
There is accumulating evidence from various sources that extracts from the milk thistle plant can be useful in the treatment of a variety of liver ailments as well as other disorders. This investigati...
Detailed Description
BIOAVAILABILTY STUDY: 1\. Clinical Protocol Screening/Informed Consent: Sixteen subjects will be recruited for the clinical protocol. All protocols, consent forms, and HIPAA forms shall be IRB-appro...
Eligibility Criteria
Inclusion
- Age range: 18-45 years old
- Race or ethnicity: no restrictions
- Health status: subjects must have no clinically significant diseases or clinically significant abnormal laboratory values as assessed during the screening medical history, physical exam, and laboratory evaluations.
- Must have no history of significant psychiatric illness or substance use.
- Written Informed Consent as well as Health Insurance Portability and Accountability Act (HIPAA) authorization forms must be signed by the eligible subject prior to the initiation of any study procedures.
Exclusion
- Any of the following conditions are cause for exclusion and/or discontinuation from the study:
- The presence of any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion.
- A positive urine pregnancy test
- The use of oral contraceptives
- The lack of use of acceptable barrier methods of birth control unless abstinent
- The use of any concomitant medication including herbal medications, over-the-counter (OTC) supplements, or a history of hypersensitivity to DM, ALPZ, TOL, or caffeine (CAF) and any history of sensitivity to milk thistle or any of its components.
- Subjects genotyped as poor metabolizers of CYP2D6 at screening
- Active smoking or use of CAF containing beverage (coffee, certain colas) for one week prior and during the study period due to known effects on CYP1A2 activity.
- Subjects expressing inability to conform to dietary restrictions required for the study
- The use of any illicit drugs or habitual consumption of large quantities of ethanol (\> 3 drinks/day)
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00200798
Start Date
May 1 2006
End Date
August 1 2007
Last Update
July 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina, GCRC
Charleston, South Carolina, United States, 29425